Search Results - "RADFORD, A. J"

Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors by Cooke, R, Jones, M E, Cunningham, D, Falk, S J, Gilson, D, Hancock, B W, Harris, S J, Horwich, A, Hoskin, P J, Illidge, T, Linch, D C, Lister, T A, Lucraft, H H, Radford, J A, Stevens, A M, Syndikus, I, Williams, M V, Swerdlow, A J

“…Background: Women treated with supradiaphragmatic radiotherapy (sRT) for Hodgkin lymphoma (HL) at young ages have a substantially increased breast cancer risk…”
Get full text

Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma : A multicenter phase II study by COIFFIER, B, HAIOUN, C, CAPDEVILLE, R, DIEHL, V, REYES, F, KETTERER, N, ENGERT, A, TILLY, H, MA, D, JOHNSON, P, LISTER, A, BUSKE, M. F, RADFORD, J. A

“…Rituximab, a chimeric monoclonal antibody that binds specifically to the CD20 antigen, induced objective responses in 50% of patients with low-grade or…”
Get full text

Does stretching increase ankle dorsiflexion range of motion? A systematic review by Radford, J A, Burns, J, Buchbinder, R, Landorf, K B, Cook, C

“…Background: Many lower limb disorders are related to calf muscle tightness and reduced dorsiflexion of the ankle. To treat such disorders, stretches of the…”
Get full text

Acquisition of biologically relevant gene expression data by Affymetrix microarray analysis of archival formalin-fixed paraffin-embedded tumours by Linton, K M, Hey, Y, Saunders, E, Jeziorska, M, Denton, J, Wilson, C L, Swindell, R, Dibben, S, Miller, C J, Pepper, S D, Radford, J A, Freemont, A J

“…Robust protocols for microarray gene expression profiling of archival formalin-fixed paraffin-embedded tissue (FFPET) are needed to facilitate research when…”
Get full text

Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma by Radford, JA, Lieberman, BA, Brison, DR, Smith, ARB, Critchlow, JD, Russell, SA, Watson, AJ, Clayton, JA, Harris, M, Gosden, RG, Shalet, SM

“…Infertility is a common late effect of chemotherapy and radiotherapy, and has a substantial effect on the quality of life for young survivors of cancer. For…”
Get full text

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group by Judson, I, Radford, J.A, Harris, M, Blay, J.-Y, van Hoesel, Q, le Cesne, A, van Oosterom, A.T, Clemons, M.J, Kamby, C, Hermans, C, Whittaker, J, Donato di Paola, E, Verweij, J, Nielsen, S

“…CAELYX®/DOXIL®, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types…”
Get full text

The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage by Howell, S J, Searle, C, Goode, V, Gardener, T, Linton, K, Cowan, R A, Harris, M A, Hopwood, P, Swindell, R, Norman, A, Kennedy, J, Howell, A, Wardley, A M, Radford, J A

“…Background: Supradiaphragmatic radiotherapy (SRT) to treat Hodgkin's lymphoma (HL) at a young age increases the risk of breast cancer (BC). A national…”
Get full text

Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma by DAVIES, A. J, ROHATINER, A. Z. S, MATHER, S. J, CLAYTON, J, FOLEY, R, JAN, H, KROLL, S, HARRIS, M, AMESS, J, NORTON, A. J, LISTER, T. A, RADFORD, J. A, HOWELL, S, BRITTON, K. E, OWENS, S. E, MICALLEF, I. N, DEAKIN, D. P, CARRINGTON, B. M, LAWRANCE, J. A, VINNICOMBE, S

“…An open-label phase II study was conducted at two centers to establish the efficacy and safety of tositumomab and iodine I 131 tositumomab at first or second…”
Get full text

International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas : Report of the jury by SHIPP, M. A, ABELOFF, M. D, SYMANN, M, ARMITAGE, J. O, PHILIP, T, COIFFIER, B, ANTMAN, K. H, CARROLL, G, HAGENBEEK, A, LOEFFLER, M, MONTSERRAT, E, RADFORD, J. A, SALLES, G, SCHMITZ, N

Get full text

Testicular Function After Cytotoxic Chemotherapy: Evidence of Leydig Cell Insufficiency by HOWELL, S. J, RADFORD, J. A, RYDER, W. D. J, SHALET, S. M

“…To evaluate testicular function in men after treatment with cytotoxic chemotherapy. We measured testosterone, sex hormone-binding globulin (SHBG), luteinizing…”
Get full text

European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic Lymphoma by FORAN, J. M, ROHATINER, A. Z. S, RADFORD, J. A, BESSELL, E. M, SOULEAU, B, BENZOHRA, A, LISTER, T. A, CUNNINGHAM, D, POPESCU, R. A, SOLAL-CELIGNY, P, GHIELMINI, M, COIFFIER, B, JOHNSON, P. W. M, GISSELBRECHT, C, REYES, F

“…Mantle-cell lymphoma (MCL), immunocytoma (IMC), and small B-cell lymphocytic lymphoma (SLL) are B-cell malignancies that express CD20 and are incurable with…”
Get full text

Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy by Howell, S. J., Radford, J. A., Adams, J. E., Smets, E. M. A., Warburton, R., Shalet, S. M.

“…OBJECTIVE Testosterone deficiency is associated with significant morbidity, and androgen replacement in overt hypogonadism is clearly beneficial. However,…”
Get full text

Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas by VOSE, J. M, WAHL, R. L, SALEH, M, ROHATINER, A. Z, KNOX, S. J, RADFORD, J. A, ZELENETZ, A. D, TIDMARSH, G. F, STAGG, R. J, KAMINSKI, M. S

“…This multicenter phase II study evaluated the efficacy, dosimetry methodology, and safety of iodine-131 tositumomab in patients with…”
Get full text

Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519) by Owadally, W.S., Sydes, M.R., Radford, J.A., Hancock, B.W., Cullen, M.H., Stenning, S.P., Johnson, P.W.M.

“…This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with…”
Get full text

Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL) by Betticher, DC, Martinelli, G, Radford, JA, Kaufmann, M, Dyer, MJS, Kaiser, U, Aulitzky, WE, Beck, J, von Rohr, A, Kovascovics, T, Cogliatti, SB, Cina, S, Maibach, R, Cerny, T, Linch, DC

“…Introduction: Sequential high dose (SHiDo) chemotherapy with stem cell support has been shown to prolong the event-free survival in patients with diffuse large…”
Get full text

Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma by Clamp, A R, Ryder, W D J, Bhattacharya, S, Pettengell, R, Radford, J A

“…The effect of utilising granulocyte colony-stimulating factor (G-CSF) to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma (NHL) on long-term…”
Get full text

Integrating personalised medicine into the routine cancer diagnostic pathway in Manchester, UK by Henry, J., Radford, J.A.

Get full text

Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial by Gleeson, M., Counsell, N., Cunningham, D., Chadwick, N., Lawrie, A., Hawkes, E.A., McMillan, A., Ardeshna, K.M., Jack, A., Smith, P., Mouncey, P., Pocock, C., Radford, J.A., Davies, J., Turner, D., Kruger, A., Johnson, P., Gambell, J., Linch, D.

“…Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is associated with a dismal prognosis. Here, we report an analysis of CNS relapse…”
Get full text

Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group by Nielsen, O.S., Judson, I., van Hoesel, Q., le Cesne, A., Keizer, H.J., Blay, J.Y., van Oosterom, A., Radford, J.A., Svancárová, L., Krzemienlecki, K., Hermans, C., van Glabbeke, M., Oosterhuis, J.W., Verweij, J.

“…In this phase II study the effect of high-dose ifosfamide (HDI) given as a 3-day continuous infusion at a dose of 12 g/m 2 repeated every 4 weeks with adequate…”
Get full text

Fatigue, sexual function and mood following treatment for haematological malignancy: the impact of mild Leydig cell dysfunction by HOWELL, S. J, RADFORD, J. A, SMETS, E. M. A, SHALET, S. M

“…Fatigue, sexual dysfunction, anxiety and depression are all more common in patients who have previously been treated with cytotoxic chemotherapy and…”
Get full text